Abemaciclib, A Selective CDK4/6 Inhibitor, Restricts the Growth of Pediatric Ependymomas
Abstract
:Simple Summary
Abstract
1. Introduction
2. Results
2.1. Exploration of Specific Therapeutic Molecules in Ependymomas
2.2. The CDK4/6 Inhibitor, Abemaciclib, Reduced Cell Proliferation and Caused Cell Death in Ependymomas
2.3. Abemaciclib Causes Significant Regression of Subcutaneous Patient-Derived Ependymoma Tumors
3. Discussion
4. Materials and Methods
4.1. Cell Culture
4.2. Biological Samples
4.3. Microarray and RNA-Seq Analysis
4.4. RNA and Reverse Transcription-Quantitative PCR
4.5. Immunoblotting and Immunohistochemistry
4.6. MTT Assay
4.7. Cell Cycle Analysis
4.8. PDX Mouse Establishment and Treatment
4.9. Statistical Analysis
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Acknowledgments
Conflicts of Interest
References
- Wong, T.T.; Ho, D.M.; Chang, K.P.; Yen, S.H.; Guo, W.Y.; Chang, F.C.; Liang, M.L.; Pan, H.C.; Chung, W.Y. Primary pediatric brain tumors: Statistics of Taipei VGH, Taiwan (1975–2004). Cancer 2005, 104, 2156–2167. [Google Scholar] [CrossRef] [PubMed]
- Liang, M.L.; Hsieh, T.H.; Liu, Y.R.; Chen, Y.W.; Lee, Y.Y.; Chang, F.C.; Lin, S.C.; Huang, M.C.; Donald Ming-Tak, H.; Wong, T.T.; et al. Significance of cyclin D1 overexpression in progression and radio-resistance of pediatric ependymomas. Oncotarget 2018, 9, 2527–2542. [Google Scholar] [CrossRef] [PubMed]
- Marinoff, A.E.; Ma, C.; Guo, D.; Snuderl, M.; Wright, K.D.; Manley, P.E.; Al-Sayegh, H.; Sinai, C.E.; Ullrich, N.J.; Marcus, K.; et al. Rethinking childhood ependymoma: A retrospective, multi-center analysis reveals poor long-term overall survival. J. Neurooncol. 2017, 135, 201–211. [Google Scholar] [CrossRef] [PubMed]
- Pejavar, S.; Polley, M.Y.; Rosenberg-Wohl, S.; Chennupati, S.; Prados, M.D.; Berger, M.S.; Banerjee, A.; Gupta, N.; Haas-Kogan, D. Pediatric intracranial ependymoma: The roles of surgery, radiation and chemotherapy. J. Neurooncol. 2012, 106, 367–375. [Google Scholar] [CrossRef]
- Grill, J.; Pascal, C.; Chantal, K. Childhood ependymoma: A systematic review of treatment options and strategies. Paediatr. Drugs 2003, 5, 533–543. [Google Scholar] [CrossRef]
- Chou, P.M.; Barquin, N.; Gonzalez-Crussi, F.; Ridaura Sanz, C.; Tomita, T.; Reyes-Mugica, M. Ependymomas in children express the multidrug resistance gene: Immunohistochemical and molecular biologic study. Pediatr. Pathol. Lab. Med. 1996, 16, 551–561. [Google Scholar] [CrossRef]
- Buccoliero, A.M.; Castiglione, F.; Rossi Degl’Innocenti, D.; Paglierani, M.; Maio, V.; Gheri, C.F.; Garbini, F.; Moncini, D.; Taddei, A.; Sardi, I.; et al. O6-Methylguanine-DNA-methyltransferase in recurring anaplastic ependymomas: PCR and immunohistochemistry. J. Chemother. 2008, 20, 263–268. [Google Scholar] [CrossRef]
- Ferguson, S.D.; Zhou, S.; Xiu, J.; Hashimoto, Y.; Sanai, N.; Kim, L.; Kesari, S.; de Groot, J.; Spetzler, D.; Heimberger, A.B. Ependymomas overexpress chemoresistance and DNA repair-related proteins. Oncotarget 2018, 9, 7822–7831. [Google Scholar] [CrossRef] [Green Version]
- Otto, T.; Sicinski, P. Cell cycle proteins as promising targets in cancer therapy. Nat. Rev. Cancer 2017, 17, 93–115. [Google Scholar] [CrossRef] [Green Version]
- Musgrove, E.A.; Caldon, C.E.; Barraclough, J.; Stone, A.; Sutherland, R.L. Cyclin D as a therapeutic target in cancer. Nat. Rev. Cancer 2011, 11, 558–572. [Google Scholar] [CrossRef]
- Santarius, T.; Shipley, J.; Brewer, D.; Stratton, M.R.; Cooper, C.S. A census of amplified and overexpressed human cancer genes. Nat. Rev. Cancer 2010, 10, 59–64. [Google Scholar] [CrossRef] [PubMed]
- Pernas, S.; Tolaney, S.M.; Winer, E.P.; Goel, S. CDK4/6 inhibition in breast cancer: Current practice and future directions. Ther. Adv. Med. Oncol. 2018, 10, 1758835918786451. [Google Scholar] [CrossRef] [Green Version]
- Beaver, J.A.; Amiri-Kordestani, L.; Charlab, R.; Chen, W.; Palmby, T.; Tilley, A.; Zirkelbach, J.F.; Yu, J.; Liu, Q.; Zhao, L.; et al. FDA Approval: Palbociclib for the Treatment of Postmenopausal Patients with Estrogen Receptor-Positive, HER2-Negative Metastatic Breast Cancer. Clin. Cancer Res. 2015, 21, 4760–4766. [Google Scholar] [CrossRef] [Green Version]
- O’Leary, B.; Finn, R.S.; Turner, N.C. Treating cancer with selective CDK4/6 inhibitors. Nat. Rev. Clin. Oncol. 2016, 13, 417–430. [Google Scholar] [CrossRef] [PubMed]
- Olmez, I.; Brenneman, B.; Xiao, A.; Serbulea, V.; Benamar, M.; Zhang, Y.; Manigat, L.; Abbas, T.; Lee, J.; Nakano, I.; et al. Combined CDK4/6 and mTOR Inhibition Is Synergistic against Glioblastoma via Multiple Mechanisms. Clin. Cancer Res. 2017, 23, 6958–6968. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Whittaker, S.; Madani, D.; Joshi, S.; Chung, S.A.; Johns, T.; Day, B.; Khasraw, M.; McDonald, K.L. Combination of palbociclib and radiotherapy for glioblastoma. Cell Death Discov. 2017, 3, 17033. [Google Scholar] [CrossRef] [PubMed]
- Olmez, I.; Zhang, Y.; Manigat, L.; Benamar, M.; Brenneman, B.; Nakano, I.; Godlewski, J.; Bronisz, A.; Lee, J.; Abbas, T.; et al. Combined c-Met/Trk Inhibition Overcomes Resistance to CDK4/6 Inhibitors in Glioblastoma. Cancer Res. 2018, 78, 4360–4369. [Google Scholar] [CrossRef] [Green Version]
- Hashizume, R.; Zhang, A.; Mueller, S.; Prados, M.D.; Lulla, R.R.; Goldman, S.; Saratsis, A.M.; Mazar, A.P.; Stegh, A.H.; Cheng, S.Y.; et al. Inhibition of DNA damage repair by the CDK4/6 inhibitor palbociclib delays irradiated intracranial atypical teratoid rhabdoid tumor and glioblastoma xenograft regrowth. Neuro Oncol. 2016, 18, 1519–1528. [Google Scholar] [CrossRef] [Green Version]
- Cook Sangar, M.L.; Genovesi, L.A.; Nakamoto, M.W.; Davis, M.J.; Knobluagh, S.E.; Ji, P.; Millar, A.; Wainwright, B.J.; Olson, J.M. Inhibition of CDK4/6 by Palbociclib Significantly Extends Survival in Medulloblastoma Patient-Derived Xenograft Mouse Models. Clin. Cancer Res. 2017, 23, 5802–5813. [Google Scholar] [CrossRef]
- Raub, T.J.; Wishart, G.N.; Kulanthaivel, P.; Staton, B.A.; Ajamie, R.T.; Sawada, G.A.; Gelbert, L.M.; Shannon, H.E.; Sanchez-Martinez, C.; De Dios, A. Brain Exposure of Two Selective Dual CDK4 and CDK6 Inhibitors and the Antitumor Activity of CDK4 and CDK6 Inhibition in Combination with Temozolomide in an Intracranial Glioblastoma Xenograft. Drug Metab. Dispos. 2015, 43, 1360–1371. [Google Scholar] [CrossRef] [Green Version]
- Gelbert, L.M.; Cai, S.; Lin, X.; Sanchez-Martinez, C.; Del Prado, M.; Lallena, M.J.; Torres, R.; Ajamie, R.T.; Wishart, G.N.; Flack, R.S.; et al. Preclinical characterization of the CDK4/6 inhibitor LY2835219: In-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine. Investig. New Drugs 2014, 32, 825–837. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Naz, S.; Sowers, A.; Choudhuri, R.; Wissler, M.; Gamson, J.; Mathias, A.; Cook, J.A.; Mitchell, J.B. Abemaciclib, a Selective CDK4/6 Inhibitor, Enhances the Radiosensitivity of Non-Small Cell Lung Cancer In Vitro and In Vivo. Clin. Cancer Res. 2018, 24, 3994–4005. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Qu, D.W.; Xu, H.S.; Han, X.J.; Wang, Y.L.; Ouyang, C.J. Expression of cyclinD1 and Ki-67 proteins in gliomas and its clinical significance. Eur. Rev. Med. Pharmacol. Sci. 2014, 18, 516–519. [Google Scholar] [PubMed]
- De Andrade, F.G.; Marie, S.K.; Uno, M.; Matushita, H.; Taricco, M.A.; Teixeira, M.J.; Rosemberg, S.; Oba-Shinjo, S.M. Immunohistochemical expression of cyclin D1 is higher in supratentorial ependymomas and predicts relapses in gross total resection cases. Neuropathology 2015, 35, 312–323. [Google Scholar] [CrossRef]
- Bollard, J.; Miguela, V.; Ruiz de Galarreta, M.; Venkatesh, A.; Bian, C.B.; Roberto, M.P.; Tovar, V.; Sia, D.; Molina-Sanchez, P.; Nguyen, C.B.; et al. Palbociclib (PD-0332991), a selective CDK4/6 inhibitor, restricts tumour growth in preclinical models of hepatocellular carcinoma. Gut 2017, 66, 1286–1296. [Google Scholar] [CrossRef] [Green Version]
- Hsieh, F.S.; Chen, Y.L.; Hung, M.H.; Chu, P.Y.; Tsai, M.H.; Chen, L.J.; Hsiao, Y.J.; Shih, C.T.; Chang, M.J.; Chao, T.I.; et al. Palbociclib induces activation of AMPK and inhibits hepatocellular carcinoma in a CDK4/6-independent manner. Mol. Oncol. 2017, 11, 1035–1049. [Google Scholar] [CrossRef]
- Michaud, K.; Solomon, D.A.; Oermann, E.; Kim, J.S.; Zhong, W.Z.; Prados, M.D.; Ozawa, T.; James, C.D.; Waldman, T. Pharmacologic inhibition of cyclin-dependent kinases 4 and 6 arrests the growth of glioblastoma multiforme intracranial xenografts. Cancer Res. 2010, 70, 3228–3238. [Google Scholar] [CrossRef] [Green Version]
- Li, X.; Seebacher, N.A.; Garbutt, C.; Ma, H.; Gao, P.; Xiao, T.; Hornicek, F.J.; Duan, Z. Inhibition of cyclin-dependent kinase 4 as a potential therapeutic strategy for treatment of synovial sarcoma. Cell Death Dis. 2018, 9, 446. [Google Scholar] [CrossRef] [Green Version]
- Whiteway, S.L.; Harris, P.S.; Venkataraman, S.; Alimova, I.; Birks, D.K.; Donson, A.M.; Foreman, N.K.; Vibhakar, R. Inhibition of cyclin-dependent kinase 6 suppresses cell proliferation and enhances radiation sensitivity in medulloblastoma cells. J. Neurooncol. 2013, 111, 113–121. [Google Scholar] [CrossRef] [Green Version]
- Valenzuela, C.A.; Vargas, L.; Martinez, V.; Bravo, S.; Brown, N.E. Palbociclib-induced autophagy and senescence in gastric cancer cells. Exp. Cell Res. 2017, 360, 390–396. [Google Scholar] [CrossRef]
- Dowless, M.; Lowery, C.D.; Shackleford, T.; Renschler, M.; Stephens, J.; Flack, R.; Blosser, W.; Gupta, S.; Stewart, J.; Webster, Y.; et al. Abemaciclib Is Active in Preclinical Models of Ewing Sarcoma via Multipronged Regulation of Cell Cycle, DNA Methylation, and Interferon Pathway Signaling. Clin. Cancer Res. 2018, 24, 6028–6039. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Iriyama, N.; Hino, H.; Moriya, S.; Hiramoto, M.; Hatta, Y.; Takei, M.; Miyazawa, K. The cyclin-dependent kinase 4/6 inhibitor, abemaciclib, exerts dose-dependent cytostatic and cytocidal effects and induces autophagy in multiple myeloma cells. Leuk. Lymphoma 2018, 59, 1439–1450. [Google Scholar] [CrossRef] [PubMed]
- Tanaka, Y.; Momose, S.; Tabayashi, T.; Sawada, K.; Yamashita, T.; Higashi, M.; Sagawa, M.; Tokuhira, M.; Rosenwald, A.; Kizaki, M.; et al. Abemaciclib, a CDK4/6 inhibitor, exerts preclinical activity against aggressive germinal center-derived B-cell lymphomas. Cancer Sci. 2020, 111, 749–759. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Chen, S.H.; Gong, X.; Zhang, Y.; Van Horn, R.D.; Yin, T.; Huber, L.; Burke, T.F.; Manro, J.; Iversen, P.W.; Wu, W.; et al. RAF inhibitor LY3009120 sensitizes RAS or BRAF mutant cancer to CDK4/6 inhibition by abemaciclib via superior inhibition of phospho-RB and suppression of cyclin D1. Oncogene 2018, 37, 821–832. [Google Scholar] [CrossRef]
- Kosovec, J.E.; Zaidi, A.H.; Omstead, A.N.; Matsui, D.; Biedka, M.J.; Cox, E.J.; Campbell, P.T.; Biederman, R.W.W.; Kelly, R.J.; Jobe, B.A. CDK4/6 dual inhibitor abemaciclib demonstrates compelling preclinical activity against esophageal adenocarcinoma: A novel therapeutic option for a deadly disease. Oncotarget 2017, 8, 100421–100432. [Google Scholar] [CrossRef]
- Kolupaeva, V.; Janssens, V. PP1 and PP2A phosphatases--cooperating partners in modulating retinoblastoma protein activation. FEBS J. 2013, 280, 627–643. [Google Scholar] [CrossRef]
- Bracken, A.P.; Ciro, M.; Cocito, A.; Helin, K. E2F target genes: Unraveling the biology. Trends Biochem. Sci. 2004, 29, 409–417. [Google Scholar] [CrossRef]
- Hafner, M.; Mills, C.E.; Subramanian, K.; Chen, C.; Chung, M.; Boswell, S.A.; Everley, R.A.; Liu, C.; Walmsley, C.S.; Juric, D.; et al. Multiomics Profiling Establishes the Polypharmacology of FDA-Approved CDK4/6 Inhibitors and the Potential for Differential Clinical Activity. Cell Chem. Biol. 2019, 26, 1067–1080. [Google Scholar] [CrossRef]
- Hino, H.; Iriyama, N.; Kokuba, H.; Kazama, H.; Moriya, S.; Takano, N.; Hiramoto, M.; Aizawa, S.; Miyazawa, K. Abemaciclib induces atypical cell death in cancer cells characterized by formation of cytoplasmic vacuoles derived from lysosomes. Cancer Sci. 2020, 111, 2132–2145. [Google Scholar] [CrossRef]
- Olsen, B.B.; Wang, S.Y.; Svenstrup, T.H.; Chen, B.P.; Guerra, B. Protein kinase CK2 localizes to sites of DNA double-strand break regulating the cellular response to DNA damage. BMC Mol. Biol. 2012, 13, 7. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Gray, G.K.; McFarland, B.C.; Rowse, A.L.; Gibson, S.A.; Benveniste, E.N. Therapeutic CK2 inhibition attenuates diverse prosurvival signaling cascades and decreases cell viability in human breast cancer cells. Oncotarget 2014, 5, 6484–6496. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Kramerov, A.A.; Golub, A.G.; Bdzhola, V.G.; Yarmoluk, S.M.; Ahmed, K.; Bretner, M.; Ljubimov, A.V. Treatment of cultured human astrocytes and vascular endothelial cells with protein kinase CK2 inhibitors induces early changes in cell shape and cytoskeleton. Mol. Cell. Biochem. 2011, 349, 125–137. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Kramerov, A.A.; Ahmed, K.; Ljubimov, A.V. Cell rounding in cultured human astrocytes and vascular endothelial cells upon inhibition of CK2 is mediated by actomyosin cytoskeleton alterations. J. Cell. Biochem. 2012, 113, 2948–2956. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Yamamoto, T.; Taira Nihira, N.; Yogosawa, S.; Aoki, K.; Takeda, H.; Sawasaki, T.; Yoshida, K. Interaction between RNF8 and DYRK2 is required for the recruitment of DNA repair molecules to DNA double-strand breaks. FEBS Lett. 2017, 591, 842–853. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Burger, K.; Ketley, R.F.; Gullerova, M. Beyond the Trinity of ATM, ATR, and DNA-PK: Multiple Kinases Shape the DNA Damage Response in Concert With RNA Metabolism. Front. Mol. Biosci. 2019, 6, 61. [Google Scholar] [CrossRef] [Green Version]
- Phi, J.H.; Choi, S.A.; Kim, S.K.; Wang, K.C.; Lee, J.Y.; Kim, D.G. Overcoming Chemoresistance of Pediatric Ependymoma by Inhibition of STAT3 Signaling. Transl. Oncol. 2015, 8, 376–386. [Google Scholar] [CrossRef] [Green Version]
- Hsieh, T.H.; Chien, C.L.; Lee, Y.H.; Lin, C.I.; Hsieh, J.Y.; Chao, M.E.; Liu, D.J.; Chu, S.S.; Chen, W.; Lin, S.C.; et al. Downregulation of SUN2, a novel tumor suppressor, mediates miR-221/222-induced malignancy in central nervous system embryonal tumors. Carcinogenesis 2014, 35, 2164–2174. [Google Scholar] [CrossRef] [Green Version]
- Ho, D.M.; Shih, C.C.; Liang, M.L.; Tsai, C.Y.; Hsieh, T.H.; Tsai, C.H.; Lin, S.C.; Chang, T.Y.; Chao, M.E.; Wang, H.W.; et al. Integrated genomics has identified a new AT/RT-like yet INI1-positive brain tumor subtype among primary pediatric embryonal tumors. BMC Med. Genom. 2015, 8, 32. [Google Scholar] [CrossRef]
- Lin, Y.C.; Chen, M.C.; Hsieh, T.H.; Liou, J.P.; Chen, C.H. CK1delta as a potential therapeutic target to treat bladder cancer. Aging 2020, 12, 5764–5780. [Google Scholar] [CrossRef]
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Liang, M.-L.; Chen, C.-H.; Liu, Y.-R.; Huang, M.-H.; Lin, Y.-C.; Wong, T.-T.; Lin, S.-E.; Chu, S.-S.; Ding, Y.-H.; Hsieh, T.-H. Abemaciclib, A Selective CDK4/6 Inhibitor, Restricts the Growth of Pediatric Ependymomas. Cancers 2020, 12, 3597. https://doi.org/10.3390/cancers12123597
Liang M-L, Chen C-H, Liu Y-R, Huang M-H, Lin Y-C, Wong T-T, Lin S-E, Chu S-S, Ding Y-H, Hsieh T-H. Abemaciclib, A Selective CDK4/6 Inhibitor, Restricts the Growth of Pediatric Ependymomas. Cancers. 2020; 12(12):3597. https://doi.org/10.3390/cancers12123597
Chicago/Turabian StyleLiang, Muh-Lii, Chun-Han Chen, Yun-Ru Liu, Man-Hsu Huang, Yu-Chen Lin, Tai-Tong Wong, Sey-En Lin, Shing-Shiung Chu, Yi-Huei Ding, and Tsung-Han Hsieh. 2020. "Abemaciclib, A Selective CDK4/6 Inhibitor, Restricts the Growth of Pediatric Ependymomas" Cancers 12, no. 12: 3597. https://doi.org/10.3390/cancers12123597